|
Real-time Estimate
Cboe BZX
17:08:31 18/09/2026 +03
|
5-day change | 1st Jan Change | ||
| 2.825 USD | -1.91% |
|
+2.67% | +4.91% |
| 08-19 | BMO Capital Initiates Perspective Therapeutics at Outperform | MT |
| 08-14 | BofA Securities Adjusts Perspective Therapeutics Price Target to $5 From $6 | MT |
Company Valuation: Perspective Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 55.03 | 35.12 | 112.8 | 215.6 | 204.4 | 328.8 | - | - |
| Change | - | -36.19% | 221.19% | 91.16% | -5.18% | 60.82% | - | - |
| Enterprise Value (EV) 1 | 55.03 | 35.12 | 112.8 | -8.207 | 61.26 | 162.2 | 97.9 | 166.2 |
| Change | - | -36.19% | 221.19% | -107.28% | 846.48% | 164.77% | -39.65% | 69.8% |
| P/E | -12.9x | -4.94x | -2.36x | -2.59x | -1.96x | -2.88x | -2.73x | -2.85x |
| PBR | - | - | - | 0.78x | 0.99x | 1.39x | 1.34x | 1.56x |
| PEG | - | -0.1x | -0x | 0.1x | -0.1x | 0.1x | -0.52x | 0.73x |
| Capitalization / Revenue | 5.47x | 9.89x | 78.7x | 148x | 231x | 1,027x | 830x | 356x |
| EV / Revenue | 5.47x | 9.89x | 78.7x | -5.64x | 69.3x | 507x | 247x | 180x |
| EV / EBITDA | -19.1x | - | - | 0.13x | -0.56x | -1.3x | -0.7x | -1.15x |
| EV / EBIT | -16x | - | -2.75x | 0.12x | -0.54x | -1.31x | -0.69x | -1.11x |
| EV / FCF | - | - | -2.97x | 0.11x | -0.64x | -1.46x | -0.68x | -1.1x |
| FCF Yield | - | - | -33.7% | 886% | -155% | -68.6% | -147% | -91.1% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.3 | -0.5 | -1.7 | -1.23 | -1.4 | -1.001 | -1.053 | -1.012 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 10.05 | 3.552 | 1.434 | 1.454 | 0.884 | 0.3201 | 0.3962 | 0.9246 |
| EBITDA 1 | -2.874 | - | - | -64.49 | -110.3 | -124.5 | -139 | -144.5 |
| EBIT 1 | -3.446 | - | -40.94 | -66.8 | -113.6 | -123.9 | -142.2 | -149.9 |
| Net income 1 | -3.39 | - | -46.51 | -79.28 | -103.1 | -114.8 | -135.2 | -142.2 |
| Net Debt 1 | - | - | - | -223.8 | -143.2 | -166.6 | -230.9 | -162.5 |
| Reference price 2 | 3.878 | 2.471 | 4.020 | 3.190 | 2.750 | 2.880 | 2.880 | 2.880 |
| Nbr of stocks (in thousands) | 14,192 | 14,211 | 28,057 | 67,588 | 74,338 | 114,152 | - | - |
| Announcement Date | 9/21/21 A | 5/1/23 A | 3/28/24 A | 3/26/25 A | 3/16/26 A | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.88x | 506.78x | -1.3x | -.--% | 329M | |
| 31.85x | 5.73x | 17.17x | 1.02% | 46.18B | |
| 34.7x | 3.34x | 14.42x | -.--% | 44.35B | |
| -20.15x | 232.19x | -21.56x | -.--% | 42.21B | |
| 46.3x | 5.35x | 29.28x | -.--% | 40.19B | |
| 27.32x | 7.86x | 20.08x | 0.42% | 29.83B | |
| 34.98x | 5.74x | 26.08x | -.--% | 17.17B | |
| 25.63x | 2.2x | 9.55x | 1.04% | 15.32B | |
| 28.8x | 1.89x | 11.64x | -.--% | 13.09B | |
| Average | 22.95x | 85.68x | 11.71x | 0.28% | 27.63B | |
| Weighted average by Cap. | 24.95x | 44.18x | 12.24x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CATX Stock
- Valuation Perspective Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
